Botanix Pharmaceuticals Ltd

Capital Structure and Liquidity Botanix has a current ratio of 4.0, indicating strong short-term liquidity. However, the company has a negative net cash position after subtracting total debt, which raises liquidity concerns. The debt-to-equity ratio is 0.29, suggesting a relatively low level of leverage. ### Profitability and Returns The company reported a net loss of AUD 86.4 million for the latest period, with an operating loss of AUD 88.0 million. Return on equity (ROE) is -106.27%, and return on assets (ROA) is -66.92%, both significantly below industry norms for pharmaceutical firms. ### Segments and Geographic Exposure Botanix's revenue is concentrated in its dermatology product portfolio, with no disclosed geographic diversification in the provided data. The company's lead product, Sofdra, is currently the primary revenue driver. ### Growth Trajectory The company is in a development phase with multiple pipeline products, including BTX 1503 for acne, BTX 1702 for rosacea, and BTX 1801 for MRSA. However, the current financials show a negative growth trajectory, with significant operating and net losses. ### Risk Factors The company faces medium liquidity risk due to its negative net cash position and high operating cash outflows. Analysts have assigned a mean recommendation of 2.00, indicating a neutral stance, with no strong buy ratings. The dilution risk is currently assessed as low. ### Recent Events Recent analyst estimates show a wide range of price targets, from AUD 0.14 to AUD 1.00, with a mean of AUD 0.49 and a median of AUD 0.33. No recent filings or transcripts are provided in the input data to detail specific events.